SCHEMBL29818360

SCHEMBL29818360

CC(C)(O)c1ncc(Br)cc1Cl

nearest known ligand 0.43

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PLAU P00749 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.33
KMT2A Q03164 3/20 0.32
HTT P42858 2/20 0.32
MEN1 O00255 2/20 0.32
POLB P06746 3/20 0.31
KDM4E B2RXH2 2/20 0.31
MAPT P10636 2/20 0.31
S1PR1 P21453 1/20 0.31
S1PR3 Q99500 1/20 0.31
ALDH1A1 P00352 1/20 0.31
LMNA P02545 1/20 0.31
PKM P14618 1/20 0.31
APOBEC3G Q9HC16 1/20 0.31
HSD11B1 P28845 1/20 0.31
HSD17B10 Q99714 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25206015 1.00 PLAU (0.43) PLAUSMN1; SMN2KMT2AHTTMEN1
SCHEMBL21718921 0.84 PLAU (0.42) PLAUSMN1; SMN2KMT2AHTTMEN1
SCHEMBL29268175 0.81 PLAU (0.40) PLAUSMN1; SMN2KMT2AHTTMEN1
SCHEMBL29989503 0.81 PLAU (0.40) PLAUSMN1; SMN2KMT2AHTTMEN1
SCHEMBL16654525 0.81 PLAU (0.40) PLAUSMN1; SMN2KMT2AHTTMEN1
SCHEMBL17186974 0.80 PLAU (0.40) PLAUSMN1; SMN2KMT2AHTTMEN1
SCHEMBL5254693 0.80 S1PR1 (0.36) PLAUSMN1; SMN2KMT2AHTTMEN1
SCHEMBL364528 0.78 HSD17B10 (0.34) HSD17B10
SCHEMBL2147947 0.78 HTT (0.33) PLAUSMN1; SMN2KMT2AHTTMAPT
SCHEMBL22140337 0.77 KMT2A (0.41) PLAUSMN1; SMN2KMT2AHTTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4284804-A1 TRICYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF CANCER, AUTOIMMUNE AND INFLAMMATORY DISORDERS Schrödinger, Inc. (US) 2023-12-06 EP disclosed
CN-117120442-A Tricyclic compounds useful for treating cancer, autoimmune disorders, and inflammatory disorders 薛定谔公司 2023-11-24 CN disclosed
WO-2022164789-A9 TRICYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF CANCER, AUTOIMMUNE AND INFLAMMATORY DISORDERS SCHRÖDINGER, INC. (US) 2023-05-25 WO disclosed
WO-2022164789-A1 TRICYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF CANCER, AUTOIMMUNE AND INFLAMMATORY DISODERS SCHRÖDINGER, INC. (US) 2022-08-04 WO disclosed